FY2024 Earnings Forecast for Affimed Issued By HC Wainwright

Affimed (NASDAQ:AFMD) – Stock analysts at HC Wainwright lifted their FY2024 EPS estimates for Affimed in a research note issued to investors on Wednesday, December 18th. HC Wainwright analyst S. Ramakanth now forecasts that the biopharmaceutical company will earn ($4.28) per share for the year, up from their previous forecast of ($4.31). HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Affimed’s current full-year earnings is ($4.00) per share. HC Wainwright also issued estimates for Affimed’s Q4 2024 earnings at ($0.93) EPS, Q3 2025 earnings at ($0.91) EPS, Q4 2025 earnings at ($0.67) EPS and FY2025 earnings at ($3.02) EPS.

AFMD has been the subject of a number of other reports. Wells Fargo & Company lowered their price target on Affimed from $20.00 to $15.00 and set an “overweight” rating for the company in a report on Thursday, December 12th. Cantor Fitzgerald restated an “overweight” rating on shares of Affimed in a research report on Tuesday, November 19th. Finally, Stifel Nicolaus lowered their price objective on shares of Affimed from $5.00 to $4.00 and set a “hold” rating for the company in a research report on Friday, November 15th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $13.50.

Affimed Stock Performance

Shares of AFMD stock opened at $1.19 on Monday. The company has a quick ratio of 1.93, a current ratio of 1.93 and a debt-to-equity ratio of 0.13. Affimed has a one year low of $1.14 and a one year high of $8.95. The company’s 50-day simple moving average is $2.92 and its 200-day simple moving average is $4.02.

Institutional Investors Weigh In On Affimed

A number of hedge funds have recently made changes to their positions in AFMD. FMR LLC boosted its position in Affimed by 30.0% during the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after acquiring an additional 4,086 shares during the period. Choreo LLC acquired a new position in Affimed during the 2nd quarter valued at about $54,000. Intellectus Partners LLC raised its position in shares of Affimed by 12.2% during the 3rd quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock worth $317,000 after buying an additional 10,250 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Affimed in the 3rd quarter worth approximately $44,000. Finally, Point72 Asset Management L.P. boosted its holdings in shares of Affimed by 4.6% in the third quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after acquiring an additional 15,108 shares in the last quarter. Institutional investors own 30.82% of the company’s stock.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.